罗氏的Gazyva/ Gazyvaro显示出明显优于常规治疗活跃性狼性炎的结果. Roche's Gazyva/Gazyvaro showed significantly better outcomes than standard treatments for active lupus nephritis.

Roche's Gazyva/Gazyvaro比对活性脑膜炎的标准治疗结果好。 脑膜炎是一种肾病,影响许多年轻妇女,尤其是有色妇女。 Roche's Gazyva/Gazyvaro showed better results than standard treatments for active lupus nephritis, a kidney disorder affecting many younger women, especially women of color. 在一项主要研究中,使用Gazyva/Gazyvaro+标准疗法的病人中有46.4%完全康复,而仅使用标准疗法的病人有33.1%。 In a major study, 46.4% of patients using Gazyva/Gazyvaro plus standard therapy had a complete recovery, compared to 33.1% using standard therapy alone. 调查结果发表在《新英格兰医学期刊》上。 The findings were published in the New England Journal of Medicine.